MedTrace Logo

Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT

NCT05023265 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-28

No results posted yet for this study

Summary

This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).

Conditions

Interventions

RADIATION

Stereotactic body radiotherapy

SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.

Sponsors & Collaborators

  • Juravinski Cancer Center

    collaborator OTHER

  • Health Sciences North

    collaborator OTHER

  • Grand River Regional Cancer Centre

    collaborator OTHER

  • British Columbia Cancer Agency

    collaborator OTHER

  • London Health Sciences Centre

    collaborator OTHER

  • Durham Regional Cancer Centre

    collaborator UNKNOWN

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • William Chu, MD, FRCPC · Sunnybrook Health Sciences Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-08
Primary Completion
2026-10-01
Completion
2026-10-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05023265 on ClinicalTrials.gov